Search Results
Results found for "Ermium Therapeutics"
- Dr. Arthur Christopoulos | Dr. GPCR Ecosystem
Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic
- Dr. Terry Hebert: How Cellular Background and Localization Influence GPCR Function | Dr. GPCR Ecosystem
Terry Hebert is a Professor of Pharmacology and Therapeutics at McGill University. The goal is to test therapeutic strategies targeting the AT1R, alpha-adrenergic, and beta-adrenergic
- FAQ | Dr. GPCR Ecosystem
Each session explores mechanistic models, translational challenges, and real-world therapeutic implications
- Dr. John Streicher: Reorganizing Opioid Signaling Beyond the Receptor | Dr. GPCR Ecosystem
Current lines of work include isoform-selective HSP90 inhibition as a strategy for widening the opioid therapeutic This is not a quirk — it is the central clue the lab has built a therapeutic strategy around.
- Scaling GLP 1 Receptor Tools Through Academia Industry Collaboration | Dr. GPCR Ecosystem
By integrating advanced tools and translational biology, his work directly informs therapeutic strategies
- Our History | Dr. GPCR Ecosystem
Sep 20, 2022 — First contributor article published: Therapeutic validation of an orphan G protein‐coupled
- GPCR Webinars | Dr. GPCR Ecosystem
Each session explores mechanistic models, translational challenges, and real-world therapeutic implications
- GPCR Masterclass: Advanced Pharmacology & Drug Discovery | Dr. GPCR
Unconventional GPCR Ligands <p class="font_8">Watch Now</p> Terry Kenakin The New Frontier of GPCR Therapeutics
- GPCRs and the Science Behind Pain and Recovery with Dr. Alex Serafini | Dr. GPCR Ecosystem
analysis, revealed nuanced roles of RGS4, RGS9, and RGSZ — not just as modulators but as potential therapeutic
- Hacking GPCRs: Tools, Tech & Drug Discovery with Tom Sakmar & Ilana Kotliar | Dr. GPCR Ecosystem
This could accelerate discovery of therapeutic targets by combining multiplex data with focused downstream
- When to Walk, When to Run: Lessons from the GPCR Trenches with Dr. Ben Clements | Dr. GPCR Ecosystem
Clements' work is primarily focused on translational developments of small molecule therapeutics, and
- Dr. Aaron Sato: Synthetic Antibody Libraries for the Hardest GPCR Targets | Dr. GPCR Ecosystem
record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics
- Dr. Joseph Kim: Structural Biology and Drug Discovery at GPCRs | Dr. GPCR Ecosystem
structural biology and drug discovery, where molecular structures inform the design and development of new therapeutics You could easily imagine separate therapeutic programs targeting those different physiological effects
- Dr. Amynah Pradhan: The Delta Opioid Receptor and the Migraine Paradox | Dr. GPCR Ecosystem
Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic
- Dr. J. Silvio Gutkind: When GPCRs Drive Cancer | Dr. GPCR Ecosystem
The canonical assumption that targeting PLC would be therapeutic has failed in the clinic, and patients
- Dr. Foord: Serendipity, RAMPs, And Industrial GPCR Pharmacology | Dr. GPCR Ecosystem
Later hepatotoxicity concerns and the success of antibody therapeutics further shifted strategy.
- Dr. Yamina Berchiche: Beyond the Lab — From Chemokine Receptors to the Dr. GPCR Ecosystem | Dr. GPCR Ecosystem
has reached only about 166 of them, leaving more than 250 receptors unstudied at anything close to therapeutic
- Revvity | Dr. GPCR Ecosystem
Whether you’re decoding signaling pathways or designing the next generation of therapeutics, Revvity
- Dr. Anita Nivedha: Computational Dynamics of Ligand Bias in GPCR Signaling | Dr. GPCR Ecosystem
visualization to become quantitative tools for understanding receptor activation and guiding GPCR-targeted therapeutics
